On August 17, 2018 ITUS Corporation (NASDAQ: ITUS) reported that CEO, Dr. Amit Kumar, will be presenting at the Next Generation Dx Summit in Washington, D.C., being held on August 20th-24th (Press release, Anixa Biosciences, AUG 17, 2018, View Source [SID1234530492]). Dr. Kumar’s presentation, "Liquid Biopsy based on Flow Cytometry and Artificial Intelligence to Detect the Existence of a Solid Tumor," is scheduled at 2:50 PM EDT, Wednesday, August 22nd. Dr. Kumar will discuss ITUS’s latest data on its Cchek diagnostic development, including studies on breast cancer and prostate cancer, as well as data from the collaborative study with Memorial Sloan Kettering and Serametrix.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This conference is focused on a number of diagnostic technologies including liquid biopsy and early cancer detection. This is the first commercial conference where we will be presenting our technology to a concentrated audience of industry players," stated Dr. Kumar. "We are pleased with the scientific progress achieved thus far with Cchek, and we remain confident that we will begin preliminary regulatory discussions with the FDA by the end of the year," added Dr. Kumar.
Dr. Kumar further stated, "With both of our programs–Cchek cancer diagnostic and CAR-T treatment for ovarian cancer—heading toward initial FDA discussions by the end of the year, we are excited about the impact we could have on the fight against cancer. Any day now, we are expecting to hear back from the FDA regarding the request, by us and our partner Moffitt Cancer Center, for a pre-IND meeting about our CAR-T therapy. We believe that the next few months will be a very exciting period for the Company, for our shareholders, and for cancer patients."